0000000000347217

AUTHOR

M.j. Roig-revert

showing 4 related works from this author

Sistemas genéticos para un nuevo abordaje del riesgo de progresión de la retinopatía diabética

2016

Resumen Objetivo Evaluar el riesgo de progresion de la retinopatia diabetica (RD) utilizando nuevas estrategias para obtener informacion genetica en diabeticos tipo 2 (DT2) basadas en interferencia por acido ribonucleico (ARN). Material y metodos Estudio multicentrico, prospectivo de casos-controles en 132 participantes divididos en: grupo DT2 (GDT2) con RD (+RD) y sin RD (−RD) (n = 77) y grupo control (GC) (n = 55). Tras entrevista personal y examen oftalmologico, se extrajeron lagrimas para analisis molecular (expresion de micro-ARN [miARN] [miRCURY™ ARN Isolation Kit, Qiagen]). En 18 muestras (GDT2+RD = 6; GDT2–RD = 6; GC = 6) obtuvimos librerias de 137 vs. 140 pares de bases (GeneMapper…

0301 basic medicine03 medical and health sciencesOphthalmology030104 developmental biology0302 clinical medicine030221 ophthalmology & optometryArchivos de la Sociedad Española de Oftalmología
researchProduct

Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid

2017

OBJECTIVE: To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS: A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS: The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed …

MaleDegeneracion macular asociada a la edad no neovascularVisual acuityTriamcinolone acetonidegenetic structuresFluido subretinianoAngiogenesis InhibitorsFundus (eye)Triamcinolone0302 clinical medicineDegeneración macular asociada a la edad no neovascular Fluido intrarretiniano Fluido subretiniano Intraretinal fluid Intravitreal therapies Non-neovascular age related macular degeneration Spectral domain optical coherence tomography Subretinal fluid Terapias intravítreas Tomografía de coherencia óptica de dominio espectralFluorescein AngiographyTomografia de coherencia optica de dominio espectralAged 80 and overmedicine.diagnostic_testSubretinal FluidExudates and TransudatesGeneral MedicineFluorescein angiographyFluido intrarretinianoBevacizumabTreatment Outcomemedicine.anatomical_structureIntravitreal InjectionsFemalemedicine.symptomIntravitreal therapiesTomography Optical Coherencemedicine.drugSubretinal fluidmedicine.medical_specialtyBevacizumabRetinal DrusenRetinaSpectral domain optical coherence tomography03 medical and health sciencesNon-neovascular age related macular degenerationRanibizumabOphthalmologymedicineHumansAgedRetinabusiness.industryMacular degenerationmedicine.diseaseTerapias intravitreaseye diseasesSurgeryWet Macular Degeneration030221 ophthalmology & optometryIntraretinal fluidsense organsRanibizumabbusiness030217 neurology & neurosurgeryArchivos de la Sociedad Española de Oftalmología (English Edition)
researchProduct

Terapias intravítreas en degeneración macular asociada a la edad no neovascular con fluido intrarretiniano o subretiniano

2017

Resumen Objetivo Evaluar la eficacia de las terapias intravitreas en casos de degeneracion macular asociada a la edad (DMAE) atrofica con fluido intra- o subretiniano. Metodos Revisamos, de forma retrospectiva, las caracteristicas de pacientes diagnosticados de DMAE atrofica con fluido intra- o subretiniano. Examinamos las retinografias y las imagenes de tomografia de coherencia optica de dominio espectral analizando en ellas la presencia de fluido y su densidad. Descartamos la existencia de neovascularizacion coroidea mediante angiografia con fluoresceina o con verde de indocianina. Resultados Se incluyeron 14 ojos de 13 pacientes con una edad media de 72,64 anos y un seguimiento medio de …

0301 basic medicine03 medical and health sciencesOphthalmology030104 developmental biology0302 clinical medicine030221 ophthalmology & optometryArchivos de la Sociedad Española de Oftalmología
researchProduct

Genetic systems for a new approach to risk of progression of diabetic retinopathy.

2016

OBJECTIVE: To evaluate the risk of progression of diabetic retinopathy (DR) using new strategies to obtain genetic information in type 2 diabetes (T2D) based on interfering ribonucleic acid (RNA). MATERIAL AND METHODS: A prospective multicentre case-control study of 132 participants was distributed into: T2D with (+DR) or without (-DR) (T2DG; n=77), and a control group (CG; n=55). After an eye examination and personal interview, tears were collected for molecular analysis (expression of microRNAs [miRNAs] (miRCURY ARN Isolation Kit, Qiagen)]. Libraries, 137 vs. 140bp (GeneMapper, Applied Biosystems), were obtained in 18 samples (T2DG+DR=6; T2DG-DR=6; CG=6) by performing next-generation sequ…

Male0301 basic medicineOncologyMicro RNAsmedicine.medical_specialtyBiomarcadores preclinicosType 2 diabetesMicro-ARNBioinformaticsRisk AssessmentInterference by RNA03 medical and health sciencesDiabetic retinopathyInternal medicineType 2 diabetes mellitusmedicineHumansProspective StudiesFamily historyAgedDiabetic Retinopathymedicine.diagnostic_testSequence Analysis RNAbusiness.industryPre-clinical biomarkersType 2 Diabetes MellitusGenetic systemsRetinopatia diabeticaGeneral MedicineDiabetic retinopathyMiddle Agedmedicine.diseaseInterferencia por ARNMolecular analysisDiabetes mellitus tipo 2030104 developmental biologyDiabetes Mellitus Type 2Eye examinationCase-Control StudiesDisease ProgressionTearsFemalebusinessBiomarcadores preclínicos Diabetes mellitus tipo 2 Diabetic retinopathy Interference by RNA Interferencia por ARN Micro RNAs Micro-ARN Pre-clinical biomarkers Retinopatía diabética Type 2 diabetes mellitus
researchProduct